Heart Failure is a SERIOUS problem affecting 500,000 patients/year in the US alone. Left untreated, it is more fatal than cancer.
Options are limited as heart failure progresses. Medications and pacemakers help in early stages, but lose effectiveness as a patient's condition worsens. Heart transplantation is effective at end-stage, but limited to only 3,500 hearts/year. The growing field of Mechanical Circulatory Support systems offer alternatives for the cardiothoracic surgeon and interventional cardiologist.
MCS systems have made great progress over 1st generation systems. nearing heart transplantation in many respects. Adverse events, while much improved, are still troublesome and expensive and represent the greatest opportunities for improvement.
To understand and to avoid factors that contribute to adverse events and high costs and to deliver ultra-miniaturized pumps for minimally-invasive and percutaneous, endovascular deployment with the versatility to address multiple clinical needs.
Copyright © 2020 VADovations - All Rights Reserved.